PMID- 29296764
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2473-9529 (Print)
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Linking)
VI  - 1
IP  - 16
DP  - 2017 Jul 11
TI  - Antiangiogenic effects of decorin restored by unfractionated, low molecular 
      weight, and nonanticoagulant heparins.
PG  - 1243-1253
LID - 10.1182/bloodadvances.2017004333 [doi]
AB  - Pregnancies affected by preeclampsia (PE) or fetal growth restriction (FGR) 
      display increases in thrombin generation and reductions in angiogenesis and cell 
      growth. There is significant interest in the potential for low molecular weight 
      heparins (LMWHs) to reduce the recurrence of PE and FGR. However, LMWH is 
      associated with an increased risk of bleeding. Therefore, it is of vital 
      importance to determine the exact molecular function of heparins in pregnancy if 
      they are used as therapy for pregnant women. We aimed to determine this using our 
      model for PE/FGR in microvascular endothelial cells. The expression of decorin, a 
      proteoglycan, was reduced to mimic PE/FGR in these cells compared with controls. 
      Four concentrations of unfractionated heparin (UFH), LMWH, and nonanticoagulant 
      heparin (NAC) were added to determine the effect on thrombin generation, 
      angiogenesis, and cell growth. Treatment with UFH and LMWH reduced thrombin 
      generation and restored angiogenesis but decreased cell growth. Treatment with 
      NAC did not affect thrombin generation, restored angiogenesis, and showed a trend 
      toward cell growth. In conclusion, treatment with NAC produced the same, if not 
      better, results as treatment with UFH or LMWH, without the same impact on 
      coagulation. Therefore, NAC could potentially be a better therapeutic option for 
      prevention of PE/FGR in high-risk women, without the risk of the adverse effects 
      of traditional anticoagulants.
FAU - Chui, Amy K L
AU  - Chui AKL
AD  - Department of Obstetrics and Gynaecology, Sunshine Hospital, The University of 
      Melbourne, St Albans, VIC, Australia.
FAU - Gunatillake, Tilini N
AU  - Gunatillake TN
AD  - Department of Obstetrics and Gynaecology, Sunshine Hospital, The University of 
      Melbourne, St Albans, VIC, Australia.
FAU - Ignjatovic, Vera
AU  - Ignjatovic V
AD  - Department of Clinical Haematology and.
AD  - Department of Paediatrics, Murdoch Childrens Research Institute, The Royal 
      Children's Hospital, The University of Melbourne, Parkville, VIC, Australia.
FAU - Monagle, Paul T
AU  - Monagle PT
AD  - Department of Clinical Haematology and.
AD  - Department of Paediatrics, Murdoch Childrens Research Institute, The Royal 
      Children's Hospital, The University of Melbourne, Parkville, VIC, Australia.
FAU - Murthi, Padma
AU  - Murthi P
AD  - Department of Medicine, School of Clinical Sciences, Monash University, Clayton, 
      VIC, Australia.
AD  - The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, 
      Australia.
AD  - Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal 
      Women's Hospital, Parkville, VIC, Australia.
FAU - Brennecke, Shaun P
AU  - Brennecke SP
AD  - Department of Maternal-Fetal Medicine Pregnancy Research Centre, The Royal 
      Women's Hospital, Parkville, VIC, Australia.
AD  - Department of Obstetrics and Gynaecology, The Royal Women's Hospital, The 
      University of Melbourne, Parkville, VIC, Australia.
FAU - Whitelock, John M
AU  - Whitelock JM
AD  - Graduate School of Biomedical Engineering, University of New South Wales, 
      Kensington, NSW, Australia; and.
FAU - Said, Joanne M
AU  - Said JM
AD  - Department of Obstetrics and Gynaecology, Sunshine Hospital, The University of 
      Melbourne, St Albans, VIC, Australia.
AD  - Maternal Fetal Medicine, Sunshine Hospital, St Albans, VIC, Australia.
LA  - eng
PT  - Journal Article
DEP - 20170703
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
PMC - PMC5728543
COIS- Conflict-of-interest disclosure: The authors declare no competing financial 
      interests.
EDAT- 2018/01/04 06:00
MHDA- 2018/01/04 06:01
PMCR- 2017/07/03
CRDT- 2018/01/04 06:00
PHST- 2017/01/03 00:00 [received]
PHST- 2017/05/19 00:00 [accepted]
PHST- 2018/01/04 06:00 [entrez]
PHST- 2018/01/04 06:00 [pubmed]
PHST- 2018/01/04 06:01 [medline]
PHST- 2017/07/03 00:00 [pmc-release]
AID - 2017/004333 [pii]
AID - 10.1182/bloodadvances.2017004333 [doi]
PST - epublish
SO  - Blood Adv. 2017 Jul 3;1(16):1243-1253. doi: 10.1182/bloodadvances.2017004333. 
      eCollection 2017 Jul 11.